Advanced NanoTherapies Inc. (ANT), a clinical-stage medical device company, has secured a $4M Series A extension investment from an undisclosed strategic medical device company. This investment will accelerate the clinical development of its SirPlux Duo Drug-Coated Balloon (DCB) for treating de novo coronary artery disease (CAD).
Key Highlights
- ANT successfully treated its first cohort of study participants in its ADVANCE-DCB first-in-human (FIH) trial.
- The trial aims to evaluate the safety and performance of the SirPlux Duo DCB in de novo CAD.
- The strategic investment will bolster ANT’s efforts in revolutionizing treatments for coronary artery disease.
Source: PR Newswire
Notable Quotes
- “Today, we celebrate two remarkable accomplishments for ANT and SirPlux Duo DCB,” – Marwan Berrada, Co-Founder and CEO of ANT
- “The SirPlux Duo DCB could have an immense impact on how we approach coronary interventions,” – Investigator Dr. Jith Somaratne, Interventional Cardiologist at Auckland City Hospital and The Heart Group in Auckland, New Zealand
SoH's Take
- The strategic investment in ANT signifies confidence in the company’s innovative approach to treating vascular diseases using nanotechnology.
- The successful treatment of the first cohort in the ADVANCE-DCB FIH trial is a promising step forward, indicating the potential of the SirPlux Duo DCB in revolutionizing treatments for coronary artery disease.
